Vincerx Capital Surpluse vs Non Current Liabilities Total Analysis

VINC Stock

USD 0.26 0.01 4.00%

Vincerx Pharma financial indicator trend analysis is much more than just breaking down Vincerx Pharma prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Vincerx Pharma is a good investment. Please check the relationship between Vincerx Pharma Capital Surpluse and its Non Current Liabilities Total accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vincerx Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Vincerx Stock refer to our How to Trade Vincerx Stock guide.

Capital Surpluse vs Non Current Liabilities Total

Capital Surpluse vs Non Current Liabilities Total Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Vincerx Pharma Capital Surpluse account and Non Current Liabilities Total. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Vincerx Pharma's Capital Surpluse and Non Current Liabilities Total is -0.33. Overlapping area represents the amount of variation of Capital Surpluse that can explain the historical movement of Non Current Liabilities Total in the same time period over historical financial statements of Vincerx Pharma, assuming nothing else is changed. The correlation between historical values of Vincerx Pharma's Capital Surpluse and Non Current Liabilities Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Surpluse of Vincerx Pharma are associated (or correlated) with its Non Current Liabilities Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Current Liabilities Total has no effect on the direction of Capital Surpluse i.e., Vincerx Pharma's Capital Surpluse and Non Current Liabilities Total go up and down completely randomly.

Correlation Coefficient

-0.33

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Capital Surpluse

Non Current Liabilities Total

Most indicators from Vincerx Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Vincerx Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vincerx Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Vincerx Stock refer to our How to Trade Vincerx Stock guide.As of November 28, 2024, Selling General Administrative is expected to decline to about 12.9 M. The current year's Issuance Of Capital Stock is expected to grow to about (58.1 K)

	2021	2022	2023	2024 (projected)
Cost Of Revenue	340K	939K	915K	650.9K
Research Development	40.1M	52.2M	29.0M	35.3M

Cost Of Revenue Research Development

Vincerx Pharma fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Non Current Assets Total	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Net Invested Capital	Capital Stock	Net Working Capital	Common Stock	Net Debt	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Retained Earnings Total Equity	Capital Surpluse	Other Current Assets	Short Long Term Debt Total	Current Deferred Revenue
Total Assets		0.6	0.92	1.0	0.9	-0.37	0.62	0.79	0.01	0.7	0.9	0.71	0.9	1.0	0.6	1.0	0.6	-0.19	0.63	0.76	0.42	-0.01	0.01	-0.33	-0.1	-0.2
Other Current Liab	0.6		0.4	0.63	0.52	0.02	0.09	0.1	0.11	0.33	0.68	0.17	0.34	0.63	0.01	0.64	0.01	-0.18	0.02	0.2	0.2	-0.11	0.11	-0.18	0.12	0.1
Total Current Liabilities	0.92	0.4		0.89	0.97	-0.7	0.82	0.94	-0.35	0.88	0.93	0.9	1.0	0.89	0.83	0.88	0.83	0.14	0.88	0.64	0.09	0.3	-0.35	-0.09	-0.46	-0.54
Total Stockholder Equity	1.0	0.63	0.89		0.88	-0.32	0.57	0.75	0.05	0.66	0.89	0.66	0.88	1.0	0.55	1.0	0.55	-0.24	0.57	0.77	0.46	-0.05	0.05	-0.36	-0.05	-0.14
Net Tangible Assets	0.9	0.52	0.97	0.88		-0.68	0.74	0.89	-0.4	0.88	0.95	0.88	0.96	0.88	0.8	0.87	0.8	0.11	0.83	0.61	0.03	0.4	-0.4	-0.12	-0.49	-0.5
Retained Earnings	-0.37	0.02	-0.7	-0.32	-0.68		-0.88	-0.76	0.77	-0.91	-0.6	-0.9	-0.71	-0.32	-0.92	-0.3	-0.92	-0.75	-0.93	-0.02	0.62	-0.8	0.77	-0.52	0.95	0.96
Accounts Payable	0.62	0.09	0.82	0.57	0.74	-0.88		0.84	-0.42	0.93	0.71	0.95	0.84	0.57	0.92	0.56	0.92	0.59	0.93	0.2	-0.29	0.48	-0.42	0.44	-0.71	-0.86
Non Current Assets Total	0.79	0.1	0.94	0.75	0.89	-0.76	0.84		-0.41	0.85	0.76	0.94	0.95	0.75	0.93	0.73	0.93	0.18	0.94	0.65	0.02	0.46	-0.41	-0.06	-0.56	-0.6
Common Stock Total Equity	0.01	0.11	-0.35	0.05	-0.4	0.77	-0.42	-0.41		-0.53	-0.33	-0.5	-0.35	0.05	-0.54	0.08	-0.54	-0.65	-0.61	0.16	0.77	-0.8	1.0	-0.35	0.86	0.73
Common Stock Shares Outstanding	0.7	0.33	0.88	0.66	0.88	-0.91	0.93	0.85	-0.53		0.85	0.97	0.88	0.66	0.93	0.64	0.93	0.54	0.92	0.25	-0.33	0.61	-0.53	0.34	-0.76	-0.82
Non Current Liabilities Total	0.9	0.68	0.93	0.89	0.95	-0.6	0.71	0.76	-0.33	0.85		0.79	0.91	0.89	0.67	0.89	0.67	0.14	0.72	0.49	0.04	0.25	-0.33	-0.06	-0.4	-0.46
Other Stockholder Equity	0.71	0.17	0.9	0.66	0.88	-0.9	0.95	0.94	-0.5	0.97	0.79		0.91	0.66	0.98	0.65	0.98	0.47	0.97	0.37	-0.25	0.6	-0.5	0.26	-0.74	-0.8
Total Liab	0.9	0.34	1.0	0.88	0.96	-0.71	0.84	0.95	-0.35	0.88	0.91	0.91		0.88	0.85	0.86	0.85	0.14	0.89	0.65	0.09	0.31	-0.35	-0.09	-0.47	-0.55
Net Invested Capital	1.0	0.63	0.89	1.0	0.88	-0.32	0.57	0.75	0.05	0.66	0.89	0.66	0.88		0.55	1.0	0.55	-0.24	0.57	0.77	0.46	-0.05	0.05	-0.36	-0.05	-0.14
Capital Stock	0.6	0.01	0.83	0.55	0.8	-0.92	0.92	0.93	-0.54	0.93	0.67	0.98	0.85	0.55		0.53	1.0	0.49	0.98	0.35	-0.3	0.68	-0.54	0.28	-0.79	-0.82
Net Working Capital	1.0	0.64	0.88	1.0	0.87	-0.3	0.56	0.73	0.08	0.64	0.89	0.65	0.86	1.0	0.53		0.53	-0.25	0.55	0.76	0.47	-0.08	0.08	-0.37	-0.02	-0.12
Common Stock	0.6	0.01	0.83	0.55	0.8	-0.92	0.92	0.93	-0.54	0.93	0.67	0.98	0.85	0.55	1.0	0.53		0.49	0.98	0.35	-0.3	0.68	-0.54	0.28	-0.79	-0.82
Net Debt	-0.19	-0.18	0.14	-0.24	0.11	-0.75	0.59	0.18	-0.65	0.54	0.14	0.47	0.14	-0.24	0.49	-0.25	0.49		0.48	-0.63	-0.9	0.66	-0.65	0.93	-0.84	-0.89
Non Currrent Assets Other	0.63	0.02	0.88	0.57	0.83	-0.93	0.93	0.94	-0.61	0.92	0.72	0.97	0.89	0.57	0.98	0.55	0.98	0.48		0.37	-0.29	0.62	-0.61	0.23	-0.78	-0.83
Other Assets	0.76	0.2	0.64	0.77	0.61	-0.02	0.2	0.65	0.16	0.25	0.49	0.37	0.65	0.77	0.35	0.76	0.35	-0.63	0.37		0.7	-0.16	0.16	-0.78	0.2	0.21
Cash And Short Term Investments	0.42	0.2	0.09	0.46	0.03	0.62	-0.29	0.02	0.77	-0.33	0.04	-0.25	0.09	0.46	-0.3	0.47	-0.3	-0.9	-0.29	0.7		-0.78	0.77	-0.8	0.82	0.73
Retained Earnings Total Equity	-0.01	-0.11	0.3	-0.05	0.4	-0.8	0.48	0.46	-0.8	0.61	0.25	0.6	0.31	-0.05	0.68	-0.08	0.68	0.66	0.62	-0.16	-0.78		-0.8	0.47	-0.92	-0.74
Capital Surpluse	0.01	0.11	-0.35	0.05	-0.4	0.77	-0.42	-0.41	1.0	-0.53	-0.33	-0.5	-0.35	0.05	-0.54	0.08	-0.54	-0.65	-0.61	0.16	0.77	-0.8		-0.35	0.86	0.73
Other Current Assets	-0.33	-0.18	-0.09	-0.36	-0.12	-0.52	0.44	-0.06	-0.35	0.34	-0.06	0.26	-0.09	-0.36	0.28	-0.37	0.28	0.93	0.23	-0.78	-0.8	0.47	-0.35		-0.62	-0.72
Short Long Term Debt Total	-0.1	0.12	-0.46	-0.05	-0.49	0.95	-0.71	-0.56	0.86	-0.76	-0.4	-0.74	-0.47	-0.05	-0.79	-0.02	-0.79	-0.84	-0.78	0.2	0.82	-0.92	0.86	-0.62		0.94
Current Deferred Revenue	-0.2	0.1	-0.54	-0.14	-0.5	0.96	-0.86	-0.6	0.73	-0.82	-0.46	-0.8	-0.55	-0.14	-0.82	-0.12	-0.82	-0.89	-0.83	0.21	0.73	-0.74	0.73	-0.72	0.94

Click cells to compare fundamentals

Vincerx Pharma Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

When determining whether Vincerx Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vincerx Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vincerx Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vincerx Pharma Stock:

How To Invest In Vincerx

Details

Is Vincerx Stock a good investment?

Details

What is Vincerx Pharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vincerx Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Vincerx Stock refer to our How to Trade Vincerx Stock guide.

You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vincerx Pharma. If investors know Vincerx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vincerx Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.14)

Return On Assets

(0.66)

Return On Equity

(1.42)

The market value of Vincerx Pharma is measured differently than its book value, which is the value of Vincerx that is recorded on the company's balance sheet. Investors also form their own opinion of Vincerx Pharma's value that differs from its market value or its book value, called intrinsic value, which is Vincerx Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vincerx Pharma's market value can be influenced by many factors that don't directly affect Vincerx Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Vincerx Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vincerx Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vincerx Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Vincerx Capital Surpluse vs Non Current Liabilities Total Analysis

Capital Surpluse vs Non Current Liabilities Total

Capital Surpluse vs Non Current Liabilities Total Correlation Analysis

Correlation Coefficient

Capital Surpluse

Non Current Liabilities Total

Vincerx Pharma fundamental ratios Correlations

Vincerx Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Net Invested Capital	+ 1.0	Total Stockholder Equity
Net Working Capital	+ 1.0	Total Stockholder Equity

Non Currrent Assets Other	- 0.93	Retained Earnings
Short Long Term Debt Total	- 0.92	Retained Earnings Total Equity
Common Stock	- 0.92	Retained Earnings
Capital Stock	- 0.92	Retained Earnings
Common Stock Shares Outstanding	- 0.91	Retained Earnings
Cash And Short Term Investments	- 0.9	Net Debt